Clinical Trial Update: Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating intravenous BI 836826 in combination with ibrutinib in relapsed/refractory chronic lymphocytic leukemia after prior therapy; study comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• BI 836826
• Ibrutinib (ibrutinib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Leukemia, Lymphocytic, Chronic, B-Cell | Phase 1 | Status: COMPLETED | Results posted: 2020-07-24